The ultimate goal of this study is to provide evidence of the feasibility of using plasma Aβ42/Aβ40 and plasma p-Tau181 to identify individuals at high risk of AD in the community and to determine whether elevated plasma GFAP concentrations can further predict AD downstream events. Here, GFAP is linked to Alzheimer disease.